C OSBORNE to Quinazolines
This is a "connection" page, showing publications C OSBORNE has written about Quinazolines.
Connection Strength
0.969
-
Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
Score: 0.413
-
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
Score: 0.313
-
Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Oncology (Williston Park). 2011 Dec; 25(14):1422-4, 1426.
Score: 0.083
-
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32.
Score: 0.083
-
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
Score: 0.048
-
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
Score: 0.016
-
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
Score: 0.012